Literature DB >> 9824355

Fatigue in primary biliary cirrhosis.

K Cauch-Dudek1, S Abbey, D E Stewart, E J Heathcote.   

Abstract

BACKGROUND: Fatigue is a frequent and debilitating symptom in patients with primary biliary cirrhosis (PBC). AIMS: To study fatigue in relation to sleep, depression, and liver disease severity.
METHODS: Patients with PBC completed validated self report questionnaires measuring fatigue, sleep quality, depression, and functional capacity. Verbally reported fatigue and observer rated measure of depression and ursodeoxycholic acid (UDCA) use were recorded. Liver biochemistry and tests to rule out metabolic causes of fatigue were performed.
RESULTS: Mean age of the 88 patients enrolled was 57 years; 86% were female and mean duration of disease was 6.6 years. Median bilirubin was 13 micromol/l (mean 18.6). Verbally reported fatigue (for more than six months) was present in 60 patients (68%). The self rated Fatigue Severity Score (FSS) correlated well with verbally reported fatigue (p=0.0001). The FSS did not correlate with age, duration of disease, serum bilirubin, Mayo Risk Score, or UDCA use, but correlation was seen with sleep quality. Fatigued patients had more sleep problems and higher depression scores than non-fatigued patients. Self rated depression was present in 28% (17/60) of fatigued compared with 4% (1/28) of non-fatigued patients.
CONCLUSIONS: Long term fatigue affected 68% of the patients with PBC but it was not related to the severity of their liver disease. Poor sleep quality and depression were commonly associated with fatigue.

Entities:  

Mesh:

Year:  1998        PMID: 9824355      PMCID: PMC1727314          DOI: 10.1136/gut.43.5.705

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  29 in total

1.  "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician.

Authors:  M F Folstein; S E Folstein; P R McHugh
Journal:  J Psychiatr Res       Date:  1975-11       Impact factor: 4.791

2.  A rating scale for depression.

Authors:  M HAMILTON
Journal:  J Neurol Neurosurg Psychiatry       Date:  1960-02       Impact factor: 10.154

3.  The problem of fatigue in dialysis patients.

Authors:  D D Cardenas; N G Kutner
Journal:  Nephron       Date:  1982       Impact factor: 2.847

4.  Combined analysis of randomized controlled trials of ursodeoxycholic acid in primary biliary cirrhosis.

Authors:  R E Poupon; K D Lindor; K Cauch-Dudek; E R Dickson; R Poupon; E J Heathcote
Journal:  Gastroenterology       Date:  1997-09       Impact factor: 22.682

5.  One-year prevalence of psychiatric disorder in Ontarians 15 to 64 years of age.

Authors:  D R Offord; M H Boyle; D Campbell; P Goering; E Lin; M Wong; Y A Racine
Journal:  Can J Psychiatry       Date:  1996-11       Impact factor: 4.356

6.  Defective corticotropin-releasing hormone mediated neuroendocrine and behavioral responses in cholestatic rats: implications for cholestatic liver disease-related sickness behaviors.

Authors:  M G Swain; M Maric
Journal:  Hepatology       Date:  1995-11       Impact factor: 17.425

7.  Hamilton Depression Rating Scale. Extracted from Regular and Change Versions of the Schedule for Affective Disorders and Schizophrenia.

Authors:  J Endicott; J Cohen; J Nee; J Fleiss; S Sarantakos
Journal:  Arch Gen Psychiatry       Date:  1981-01

8.  Clinical, biochemical and histological features in 102 patients with chronic hepatitis C virus infection.

Authors:  I Merican; S Sherlock; N McIntyre; G M Dusheiko
Journal:  Q J Med       Date:  1993-02

9.  Lifetime prevalence of specific psychiatric disorders in three sites.

Authors:  L N Robins; J E Helzer; M M Weissman; H Orvaschel; E Gruenberg; J D Burke; D A Regier
Journal:  Arch Gen Psychiatry       Date:  1984-10

10.  Effects of ursodeoxycholic acid on survival in patients with primary biliary cirrhosis.

Authors:  K D Lindor; T M Therneau; R A Jorgensen; M Malinchoc; E R Dickson
Journal:  Gastroenterology       Date:  1996-05       Impact factor: 22.682

View more
  45 in total

Review 1.  Primary biliary cirrhosis: new perspectives in diagnosis and treatment.

Authors:  M I Prince; D E Jones
Journal:  Postgrad Med J       Date:  2000-04       Impact factor: 2.401

Review 2.  Fatigue in primary biliary cirrhosis.

Authors:  Ghulam Abbas; Roberta A Jorgensen; Keith D Lindor
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2010-05-11       Impact factor: 46.802

Review 3.  Fatigue in cholestatic liver disease--a perplexing symptom.

Authors:  D Kumar; R K Tandon
Journal:  Postgrad Med J       Date:  2002-07       Impact factor: 2.401

Review 4.  Primary biliary cirrhosis: From bench to bedside.

Authors:  Elias Kouroumalis; George Notas
Journal:  World J Gastrointest Pharmacol Ther       Date:  2015-08-06

Review 5.  Extrahepatic manifestations of cholestatic liver diseases: pathogenesis and therapy.

Authors:  Thomas Pusl; Ulrich Beuers
Journal:  Clin Rev Allergy Immunol       Date:  2005-04       Impact factor: 8.667

6.  Development, validation, and evaluation of the PBC-40, a disease specific health related quality of life measure for primary biliary cirrhosis.

Authors:  A Jacoby; A Rannard; D Buck; N Bhala; J L Newton; O F W James; D E J Jones
Journal:  Gut       Date:  2005-06-16       Impact factor: 23.059

7.  Association between fatigue and decreased survival in primary biliary cirrhosis.

Authors:  Claudia O Zein; Arthur J McCullough
Journal:  Gut       Date:  2007-08       Impact factor: 23.059

8.  Four year follow up of fatigue in a geographically defined primary biliary cirrhosis patient cohort.

Authors:  D E J Jones; N Bhala; J Burt; J Goldblatt; M Prince; J L Newton
Journal:  Gut       Date:  2005-11-18       Impact factor: 23.059

9.  PBC: Better Solutions to Beat Feeling Beat.

Authors:  Naw April Phaw; David E J Jones
Journal:  Dig Dis Sci       Date:  2019-08       Impact factor: 3.199

Review 10.  Primary biliary cirrhosis.

Authors:  Simon Hohenester; Ronald P J Oude-Elferink; Ulrich Beuers
Journal:  Semin Immunopathol       Date:  2009-07-15       Impact factor: 9.623

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.